Preadolescent non- and hyporesponders following three doses of hepatitis B vaccine need only one more dose

被引：3
作者：
Duval, B
Boulianne, N
De Serres, G
De Wals, P
Massé, R
Trudeau, G
机构：
[1] Inst Natl Sante Publ Quebec, Beauport, PQ G1E 7G9, Canada
[2] Univ Laval, Ctr Hosp Univ Quebec, Inst Natl Sante Publ Quebec, Unite Rech Sante Publ, Quebec City, PQ, Canada
[3] Minist Sante, Quebec City, PQ G1T 2K4, Canada
[4] Serv Sociaux, Quebec City, PQ G1T 2K4, Canada
来源：
VACCINE | 2002年 / 20卷 / 31-32期
关键词：
hepatitis B vaccine; revaccination; preadolescents;
D O I：
10.1016/S0264-410X(02)00377-8
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A small proportion of healthy children fail to develop antibodies against hepatitis B after three doses of vaccine. Few data are available regarding the optimal re-immunization strategy. We measured the immune response I month after a single supplementary dose of recombinant hepatitis B vaccines in 18 young preadolescents who were non- or hyporesponsive after a regular primary course of three doses of recombinant hepatitis B vaccines. Among them, 100% seroconverted and 89% reached the seroprotective titer of 10 milli-International Units (mIU)/ml. Most healthy children, particularly if they are hyporesponders, will have reached the seroprotective level after one dose and will not need further injections. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：3632 / 3634
页数：3
相关论文
共 15 条
[1]  
ANDRE FE, 1987, POSTGRAD MED J, V63, P169
[2]   Immunogenicity of hepatitis B vaccines - Implications for persons at occupational risk of hepatitis B virus infection [J].
Averhoff, F ;
Mahoney, F ;
Coleman, P ;
Schatz, G ;
Hurwitz, E ;
Margolis, H .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 1998, 15 (01) :1-8
[3]  
*CCNI, 1998, GUID CAN IMM
[4]  
*CDC, 1991, MMWR-MORBID MORTAL W, V40, P1
[5]   RESPONSE TO SUPPLEMENTARY VACCINATION WITH RECOMBINANT OR PLASMA HEPATITIS-B VACCINE IN HEALTHY NON-RESPONDING CHILDREN [J].
CHENG, KF ;
CHANG, MH ;
LEE, CY ;
HUANG, LM ;
HSU, HY ;
LEE, PI ;
CHEN, CM .
VACCINE, 1994, 12 (10) :899-902
[6]   Comparative immunogenicity under held conditions of two recombinant hepatitis B vaccines in 8-10-year-old children [J].
Duval, B ;
Boulianne, N ;
De Serres, G ;
Laflamme, N ;
De Wals, P ;
Massé, R ;
Trudeau, G ;
Delage, G ;
Desjardins, L .
VACCINE, 2000, 18 (15) :1467-1472
[7]   Randomized, comparative trial of 20 mu g vs 40 mu g Engerix B vaccine in hepatitis B vaccine non-responders [J].
Goldwater, PN .
VACCINE, 1997, 15 (04) :353-356
[8]   LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS-B VACCINE IN HOMOSEXUAL MEN [J].
HADLER, SC ;
FRANCIS, DP ;
MAYNARD, JE ;
THOMPSON, SE ;
JUDSON, FN ;
ECHENBERG, DF ;
OSTROW, DG ;
OMALLEY, PM ;
PENLEY, KA ;
ALTMAN, NL ;
BRAFF, E ;
SHIPMAN, GF ;
COLEMAN, PJ ;
MANDEL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (04) :209-214
[9]   IMMUNE-RESPONSE TO HEPATITIS-B REVACCINATION [J].
JILG, W ;
SCHMIDT, M ;
DEINHARDT, F .
JOURNAL OF MEDICAL VIROLOGY, 1988, 24 (04) :377-384
[10]   Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences .2. Immunogenicity in poor responders to hepatitis B vaccines [J].
LerouxRoels, G ;
Desombere, I ;
Cobbaut, L ;
Petit, MA ;
Desmons, P ;
Hauser, P ;
Delem, A ;
DeGrave, D ;
Safary, A .
VACCINE, 1997, 15 (16) :1732-1736
12